Ad is loading...
Ad is loading...
ADNRX vs PAMCX
ADNRX vs PAMCX Comparison
Open Charts ADNRX vs PAMCX
American Beacon ARK Transfmt Innov R6
Price$15.04
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth Adv
Price$106.63
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
ADNRX vs PAMCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
ADNRX vs. PAMCX commentary
Nov 23, 2024
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADNRX is a Sell and PAMCX is a Buy.
FUNDAMENTALS
Fundamentals
PAMCX has more cash in the bank: 31.3B vs. ADNRX (206M). ADNRX (0.00) and PAMCX (0.00) have matching dividends . ADNRX was incepted earlier than PAMCX: ADNRX (4 years) vs PAMCX (25 years). ADNRX is a more actively managed with annual turnover of: 33.00 vs. PAMCX (21.70). ADNRX has a lower initial minimum investment than PAMCX: ADNRX (0) vs PAMCX (2500). ADNRX annual gain was more profitable for investors over the last year : 24.09 vs. PAMCX (14.52).
| ADNRX | PAMCX | ADNRX / PAMCX | |
| Total Expense Ratio | N/A | N/A | - |
| Annual Report Gross Expense Ratio | N/A | N/A | - |
| Fund Existence | 4 years | 25 years | - |
| Gain YTD | 4.735 | 12.230 | 39% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2500 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 206M | 31.3B | 1% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 24.09 | 14.52 | 166% |
| Returns for 3 years | -62.84 | -14.56 | 432% |
| Returns for 5 years | N/A | 13.78 | - |
| Returns for 10 years | N/A | 33.07 | - |
View a ticker or compare two or three
VS
VS
Ad is loading...